Skip to main content
. 2020 Sep 28;14:3983–3993. doi: 10.2147/DDDT.S264077

Figure 5.

Figure 5

The effect of compound 7594–0037 on c-Myc protein stability. (A) The expression of c-Myc mRNA in RPMI-8226 and U266 cells was assessed by real-time PCR. ns, not significant. (B–C) Western blot analysis of c-Myc protein expression in RPMI-8226 and U266 cells treated with compound 7594–0037 at different time intervals. (D) U266 cells were treated with compound 7594–0037, following incubation with CHX for different amounts of time. Western blot detection of the change in c-Myc protein levels. (E–F) Western blot analyses of c-Myc expression in RPMI-8226 and U266 cells treated with compound 7594–0037 along with MG132 treatment. (G) Western blot analysis of the expression levels of PIM1, c-Myc, pS62-c-Myc, and pT58-c-Myc in U266 cells via treatment with compound 7594–0037 for different amounts of time. (H) Pearson correlation analysis of PIM1 and c-Myc mRNA levels in 44 newly diagnosed MM patients.